THI

WITH AFFIRMATIVE ACTION OUT, LANDMARK STUDY PROVIDES NEW APPROACH TO DIVERSIFYING THE PHYSICIAN WORKFORCE

Retrieved on: 
Wednesday, October 18, 2023
THI, MSMS, Association of American Medical Colleges, Science, Physician, MD, Workforce, USMLE, Research, Master of Science, MCAT, ST, Curriculum, AAMC, PHSU, University, Student, Ponce Health Sciences University, Nursing, Management, Medicine

ST. LOUIS, Oct. 18, 2023 /PRNewswire/ -- Ponce Health Sciences University (PHSU) and Tiber Health Innovation (THI) announce the publication of a report in Academic Medicine, the flagship journal of the Association of American Medical Colleges (AAMC), titled "Increasing Diversity in the Physician Workforce: Pathway Programs and Predictive Analytics."

Key Points: 
  • Two groups were compared: students who were directly admitted to PHSU MD versus students who went through MSMS before PHSU MD.
  • "MD admissions committees that rely on the MCAT can upgrade their evaluation process by implementing this data-driven, performance-based approach.
  • PHSU/THI's goal is to expand this approach across the U.S. by partnering with universities that want to offer the MSMS program to their own students.
  • PHSU/THI are seeking more universities to join the MSMS University Network and help address the lack of diversity in the physician workforce.

New Widex Study on Fractal Sound Stimulation in Hearing Aids Shows Positive Effects for Tinnitus Treatment and Overall Well-Being

Retrieved on: 
Tuesday, May 2, 2023
Music, Hearing loss, Tinnitus, THI, Relaxation, TFI, Audiology, Patient, Hearing, Kool-Aid, Education, Dentistry, Widex

HAUPPAUGE, N.Y., May 2, 2023 /PRNewswire/ -- Widex USA Inc. has published preliminary results of an ongoing study that validates the use of fractal sound stimulation, specifically new Widex SoundRelax tones, in treating tinnitus and supporting relaxation, concentration and well-being for all Widex wearers.

Key Points: 
  • has published preliminary results of an ongoing study that validates the use of fractal sound stimulation, specifically new Widex SoundRelax tones, in treating tinnitus and supporting relaxation, concentration and well-being for all Widex wearers.
  • "Widex SoundRelax is the latest evolution in our evidence-based approach to tinnitus treatment, which leverages patented fractal tones algorithmically generated within Widex hearing aids.
  • The study aims to investigate whether Widex SoundRelax tones are as efficient as Widex Zen tones in treating tinnitus severity.
  • These outcomes indicate that hearing care professionals (HCPs) can confidently recommend Widex Moment Sheer hearing aids as an all-in-one solution addressing hearing loss, tinnitus and overall well-being.

FDA Grants Lenire® Tinnitus Treatment Device De Novo Approval

Retrieved on: 
Tuesday, March 7, 2023
Real-World Evidence, US Foods, Veterans' Compensation Cost-of-Living Adjustment Act of 2013, Trial de novo, THI, Perception, Doctor, Doctor of Audiology, Hyperacusis, Patient, Surgeon, Scientific Reports, Research, University, Clinical trial, Tinnitus, Senior counsel, Food, Veteran, Kool-Aid, FDA, Minneapolis Veterans Affairs Health Care System, Trial of the century, Different, Safety, Device, ENT, De novo, Patient satisfaction, Medical device, Dentistry, Pharmaceutical industry, Audiology

CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.

Key Points: 
  • CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.
  • The De Novo approval of Lenire is significant as it acknowledges Lenire as a technological and clinical pioneer for tinnitus treatment.
  • "With this FDA approval of the Lenire device, it will provide me and tinnitus specialists across the United States with an exciting new tinnitus treatment option for our clinical toolbox," explained Dr. Jason Leyendecker (AuD).
  • "FDA approval of the Lenire Tinnitus Treatment System is a quantum leap forward in the caring of patients with bothersome tinnitus.

FDA Grants Lenire® Tinnitus Treatment Device De Novo Approval

Retrieved on: 
Tuesday, March 7, 2023
Real-World Evidence, US Foods, Veterans' Compensation Cost-of-Living Adjustment Act of 2013, Trial de novo, THI, Perception, Doctor, Doctor of Audiology, Hyperacusis, Patient, Surgeon, Scientific Reports, Research, University, Clinical trial, Tinnitus, Senior counsel, Food, Veteran, Kool-Aid, FDA, Minneapolis Veterans Affairs Health Care System, Trial of the century, Different, Safety, Device, ENT, De novo, Patient satisfaction, Medical device, Dentistry, Pharmaceutical industry, Audiology

CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.

Key Points: 
  • CHICAGO, March 7, 2023 /PRNewswire/ -- Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.
  • The De Novo approval of Lenire is significant as it acknowledges Lenire as a technological and clinical pioneer for tinnitus treatment.
  • "With this FDA approval of the Lenire device, it will provide me and tinnitus specialists across the United States with an exciting new tinnitus treatment option for our clinical toolbox," explained Dr. Jason Leyendecker (AuD).
  • "FDA approval of the Lenire Tinnitus Treatment System is a quantum leap forward in the caring of patients with bothersome tinnitus.

Global Pacemakers Pipeline Insight and Competitive Landscape 2022: Featuring Key Players Medtronic, Boston Scientific Corporation, Biotronik Se & Co, LivaNova & Abbott Laboratories - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 27, 2022
Biotechnology, Health, Medical Devices, Acquisition, Blood, Physician, Competitive landscape, Food, CRT, Metal electrode leadless face, Degenerative disease, UCLA, Implantable cardioverter-defibrillator, News, Heart failure, Food and Drug Administration, Ageing, Technology, FDA, High, Heart, Medtronic, Growth, Cardiac arrest, Population, THI, The Texas Heart Institute, Nature, Prevalence, Medical device, Oil, Artificial cardiac pacemaker

This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.

Key Points: 
  • This "Pacemakers-Pipeline Insight and 2022," report provides comprehensive insights about 20+ companies and 25+ pipeline devices in Pacemakers pipeline landscape.
  • The Pacemakers market is expected to undergo significant growth in the approaching years owning to an increasing prevalence of cardiovascular disorders around the world.
  • This report provides a detailed study of the emerging pacemakers along with competitive landscape to help better understand the emerging pacemaker devices.
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities

TurbineHub Joins the Esri Startup Program

Retrieved on: 
Friday, June 17, 2022
Satellite, Software, Environment, Alternative Energy, Energy, Data Management, Technology, Green Technology, ROCE, Wind, Industry, Fortune 500, Software as a service, Database, Technology, CEO, IOT, THI, GIS, API, Global Partners, Investment, ArcGIS, University, Return on capital employed, Internet of things, Government, Organization, Renewable energy, Pacific Ocean, Esri

TurbineHub has been selected to join the Esri Startup Program, a coveted three-year program that empowers startup partners with ArcGIS technology resources to utilize within their offerings.

Key Points: 
  • TurbineHub has been selected to join the Esri Startup Program, a coveted three-year program that empowers startup partners with ArcGIS technology resources to utilize within their offerings.
  • With these resources, TurbineHub has developed a solution to support wind energy investment and asset management, bringing new and innovative products to Esri customers.
  • TurbineHub also recently released the TurbineHub Index Number (THI), a national database of wind turbines confirmed with recent satellite imagery.
  • We are excited to partner with TurbineHub through the Esri Startup Program, said Robert Laudati, Director of Global Partners and Alliances at Esri.

Neuromod welcomes real-world evidence demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients

Retrieved on: 
Monday, February 21, 2022
Tinnitus, Sound, THI, DHZ, Hannover Medical School, Otorhinolaryngology, Clinical trial, Safety, Tongue, Founder, Trial of the century, Brain, DRS, FDA, Science Translational Medicine, Patient, CEO, Department, Dentistry, Medical device, Pharmaceutical industry

The real-world dataare consistent with the outcomes of Neuromod's large-scale clinical trial (TENT-A1), which included 326 participants.

Key Points: 
  • The real-world dataare consistent with the outcomes of Neuromod's large-scale clinical trial (TENT-A1), which included 326 participants.
  • Furthermore, there were no reported treatment-related adverse events with Lenire, confirming the device's safety in a real-world setting.
  • The TENT-A1 clinical trial, which involved 326 participants across Ireland and Germany, demonstrated Lenire's efficacy in improving participant's tinnitus symptoms.
  • Neuromod specialises in non-invasive neuromodulation technologies and has designed and developed Lenire, which has been used to treat tinnitus patients since 2019.

Neuromod welcomes real-world evidence demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients

Retrieved on: 
Monday, February 21, 2022
Tinnitus, Sound, THI, DHZ, Hannover Medical School, Otorhinolaryngology, Clinical trial, Safety, Tongue, Founder, Trial of the century, Brain, DRS, FDA, Science Translational Medicine, Patient, CEO, Department, Dentistry, Medical device, Pharmaceutical industry

DUBLIN, Feb. 21, 2022 /PRNewswire/ -- Irish medical device company, Neuromod Devices Ltd. (Neuromod), has welcomed the findings of an independent study performed at the German Hearing Center (DHZ) at Hannover Medical School, which found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms (based on the Tinnitus Handicap Inventory score[i] across 20 patients) when using the Lenire treatment device.

Key Points: 
  • The real-world dataare consistent with the outcomes of Neuromod's large-scale clinical trial (TENT-A1), which included 326 participants.
  • Furthermore, there were no reported treatment-related adverse events with Lenire, confirming the device's safety in a real-world setting.
  • The TENT-A1 clinical trial, which involved 326 participants across Ireland and Germany, demonstrated Lenire's efficacy in improving participant's tinnitus symptoms.
  • Neuromod specialises in non-invasive neuromodulation technologies and has designed and developed Lenire, which has been used to treat tinnitus patients since 2019.

Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research

Retrieved on: 
Friday, October 1, 2021
Antigen presentation, Regenerative medicine, U.S. News & World Report, The Texas Heart Institute, Chagas, Population, COVID-19 vaccine, University, Cardiovascular disease, UTMB, Vaccine, U, Chagas disease, Heart failure, Texas A&M University, Degenerative disease, Parasitism, Research, Trypanosoma cruzi, Stroke, Physician, Central nervous system, Heart, CEO, Awareness, Disease, Cardiology, Marathi, Vaccination, THI, Infection, Therapy, FDA, Health, Cell adhesion, PD-1, Risk, Organization, Education, GLOBE, Use, News, Patient, List of Nature Research journals, COVID-19, Antigen, Integrin, Howard Brody, Pharmaceutical industry, Medical imaging

Chagas is endemic in Latin America and Mexico and causes damage to the heart and to the central nervous system.

Key Points: 
  • Chagas is endemic in Latin America and Mexico and causes damage to the heart and to the central nervous system.
  • It is estimated that over 300,000 people in the United States and over 8 million worldwide are afflicted with Chagas Disease.
  • Specifically, in Texas, scientists at Texas A&M University have been studying Chagas Disease in kissing bugs since 2012 and found that 55% of over 7,000 bugs studied possessed the aforementioned parasite that causes the illness.
  • While not an overtly common ailment, Chagas is a very serious disease that can cause heart failure and stroke with lethal consequences, Dr. Woodside emphasized.

Roll Up To Win™ is here! The all-digital Tim Hortons® contest launches today with our largest prize pool ever and every Roll wins!

Retrieved on: 
Monday, March 8, 2021
Restaurants, Fast-food restaurants, Restaurant chains, Canadian culture, Restaurant Brands International, Tim Hortons, Wendy's International, TIMS, THI, Roll

TORONTO, March 8, 2021 /CNW/ -A new era for an iconic Tim Hortons tradition begins today with the start of Roll Up To Win and because we've retired the dreaded "Please Play Again" message, every Roll's a win!

Key Points: 
  • TORONTO, March 8, 2021 /CNW/ -A new era for an iconic Tim Hortons tradition begins today with the start of Roll Up To Win and because we've retired the dreaded "Please Play Again" message, every Roll's a win!
  • Guests will earn one Roll for each eligible item purchased when scanning for Tims Rewards using their Tim Hortons app or their physical Tims Rewards card.
  • Guests can reveal their Rolls to win great prizes on their Tim Hortons app or at the Roll Up To Win website.
  • "We're so excited to kick off this Roll Up reinvention that will see Tim Hortons guests win on every single Roll," said Hope Bagozzi, Chief Marketing Officer for Tim Hortons.